Autosomal dominant polycystic kidney disease

The European Medicines Agency ( EMA ) has recommended granting a marketing authorisation to Jinarc ( Tolvaptan ). Jinarc is...


The TEMPO 3:4 Trial results suggested that Tolvaptan ( Samsca ) had no effect compared with placebo on albuminuria in...


Autosomal dominant polycystic kidney disease ( ADPKD ) is a major cause of end-stage kidney failure, but is often identified...


The role of hyperuricemia in disease progression of autosomal dominant polycystic kidney disease ( ADPKD ) has not been defined...


In autosomal dominant polycystic kidney disease ( ADPKD ), progressive kidney cyst formation commonly leads to end-stage renal disease (...


Hypertension is common in autosomal dominant polycystic kidney disease ( ADPKD ) and is associated with increased total kidney volume,...


The two largest studies of mammalian target of rapamycin inhibitor treatment of autosomal dominant polycystic kidney disease ( ADPKD )...


Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant...


Significant liver injury associated with the use of Tolvaptan ( Samsca ) has been reported. In a large double-blind, 3-year,...


Drug-induced liver injury has been observed in clinical trials investigating potential use in patients with autosomal dominant polycystic kidney disease...


Vasopressin V2-receptor antagonists may delay disease progression in autosomal dominant polycystic kidney disease ( ADPKD ). Trials with V2-receptor antagonists...


The FDA ( Food and Drug Administration ) has advised healthcare professionals of significant liver injury associated with the use...